SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocketman who started this subject8/2/2002 11:55:12 PM
From: aknahow  Read Replies (1) of 9719
 
If and when you buy anything else again you should consider Xoma. Baxter will be announcing a clinical trial for a new indication, believed to be sepsis, by year end. Baxter pays 100% of development cost and Xoma will receive about 40% of gross profits if Neuprex ever makes it to market.

And of course there is Genetech's Raptiva, (Xanelim) which may see a BLA filed by year end. While Xoma is responsible for it's share of expenses, 12.5% of cost, DNA funds them and Xoma will get 25% of gross profits.

Think about it. You could do a lot worse. Of course, you already, know this.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News